The next-generation wet lab on semiconductors
Market:
AI can now design biological experiments at scale—but discovery is still restricted by slow and costly wet labs. Breaking through the wet lab limitation for biological discovery will truly enable the bioeconomy and unlock the $130B market by 2035.
Technology:
Diatom Biolab is building the Bio-Server: a semiconductor-based wet lab platform to enable Moore’s law for biological discovery.Advantages:
- Automated experiment with highest precision ever
- Miniaturized reactions (nL to pL scale)
- Scalable experiment throughput through massive parallelization
Patents Issued:
- Currently developing several IPs.
Contact:
Website: https://www.diatombio.com
Email: hello@diatombiolab.com
LinkedIn: https://linkedin.com/company/diatom-bio
Portfolio Companies
- Anaco
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- Diatom Biolab
- Eximius Diagnostics
- Giant BioSystems
- Hikari Medical Technologies
- ImmunoVec
- MedStat AI Inc.
- Mervyn's Petcare, Inc.
- Meteor Biotech, LLC
- My Block Skin, Inc.
- Nanomega CryoAI
- NEXT-TFX, Inc.
- Paralos Bioscience Inc.
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Prosper DNA
- Protean Research, Inc.
- Purpose Bio
- RaizDx
- RiboForge
- Saku Biosciences, Inc.
- SolGrapH, Inc.
- Sorriso Pharmaceuticals
- Thermeutics, Inc.
- Vault Pharma
- Veergen, Inc.
- Yuyu Bio, Inc.